|
|
Volumn 295, Issue 5559, 2002, Pages 1526-1528
|
|
Effect of p53 status on tumor response to antiangiogenic therapy
a
a
a
a
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
GENES;
TUMORS;
ANTIANGIOGENIC THERAPY;
GENETIC ENGINEERING;
ANGIOGENESIS INHIBITOR;
NEUTRALIZING ANTIBODY;
PROTEIN P53;
UNCLASSIFIED DRUG;
VASCULOTROPIN RECEPTOR 2 ANTIBODY;
VINBLASTINE;
CANCER;
GENE;
ANIMAL EXPERIMENT;
ANIMAL MODEL;
APOPTOSIS;
ARTICLE;
CANCER COMBINATION CHEMOTHERAPY;
CANCER IMMUNOTHERAPY;
COLORECTAL CANCER;
CONTROLLED STUDY;
DRUG RESPONSE;
GENE INACTIVATION;
HUMAN;
HUMAN CELL;
MOUSE;
NONHUMAN;
PRIORITY JOURNAL;
TUMOR SUPPRESSOR GENE;
TUMOR VASCULARIZATION;
ANGIOGENESIS INHIBITORS;
ANIMALS;
ANTIBODIES;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
APOPTOSIS;
CELL HYPOXIA;
CELL SURVIVAL;
COLORECTAL NEOPLASMS;
CYCLIN-DEPENDENT KINASE INHIBITOR P21;
CYCLINS;
GENE DELETION;
GENE SILENCING;
GENES, P53;
HUMANS;
IN SITU NICK-END LABELING;
MICE;
MICE, SCID;
NEOPLASM TRANSPLANTATION;
NEOPLASMS, EXPERIMENTAL;
RECEPTOR PROTEIN-TYROSINE KINASES;
RECEPTORS, GROWTH FACTOR;
RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR;
TUMOR CELLS, CULTURED;
TUMOR SUPPRESSOR PROTEIN P53;
VINBLASTINE;
ANIMALIA;
|
|
EID: 0037154738
PISSN: 00368075
EISSN: None
Source Type: Journal
DOI: 10.1126/science.1068327 Document Type: Article |
|
Times cited : (418)
|
|
References (32)
|
